Toshiko Nakai

Dr. Toshiko Nakai

Nihon University School of Medicine
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Journal of Cardiology
Verified
Journal Article
Open access
TNToshiko Nakai
Toshiko Nakai
YIYukitoshi Ikeya
Yukitoshi Ikeya
RKRikitake Kogawa
Rikitake Kogawa
YOYasuo Okumura
Yasuo Okumura
Cardiac resynchronization therapy (CRT) has been established as a standard treatment for heart failure. The effectiveness of CRT has been shown in many clinical trials and realized in actual clinical practice. Nevertheless, underutilization of CRT is a major problem in the treatment of heart failure. One factor leading to underutilization is the existence of CRT non-responders. CRT non-response has been discussed for approximately 20 years, since CRT was introduced. Since the beginning, the CRT non-response rate has been reported to be 30%. However, we are now undergoing a major transformation in the thinking about CRT response. First, heart failure is a progressive disease. Like many medications for heart failure, CRT does not cure the underlying disease of heart failure. Considering the natural course of heart failure, it is easy to understand that there will definitely be non-responders. There might have been misunderstandings about how to determine CRT response. Although CRT is a treatment for heart failure, it does not cure heart failure or myocardial tissue damage. Instead, by correcting conduction disorders and dyssynchrony, it modifies factors that exacerbate heart failure, which contributes to improvement. In addition, it is important to realize that pacing is the only treatment for correcting conduction disorders. Thus, in theory, CRT is an essential treatment for heart failure at any stage, regardless of severity, when it is accompanied by conduction disorder. Here, we consider the current state of CRT and the causes of underutilization. Returning to the origin of CRT, reconsidering the effects of CRT and the thinking about response, and spreading a new way of thinking will lead to the proper utilization of CRT.

1 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TNToshiko Nakai
Toshiko Nakai
YIYukitoshi Ikeya
Yukitoshi Ikeya
RKRikitake Kogawa
Rikitake Kogawa
NONaoto Otsuka
Naoto Otsuka
YWYuji Wakamatsu
Yuji Wakamatsu
YOYasuo Okumura
Yasuo Okumura
Background: The definition of response to cardiac resynchronization therapy (CRT) varies across clinical trials. There are two main definitions, i.e., echocardiographic response and functional response. We assessed which definition was more reasonable. Methods: In this study of 260 patients who had undergone CRT, an echocardiographic response was defined as a reduction in a left ventricular end-systolic volume of greater than or equal to 15% or an improvement in left ventricular ejection fraction of greater than or equal to 5%. A functional response was defined as an improvement of at least one class category in the New York Heart Association functional classification. We assessed the response to CRT at 6 months after device implantation, based on each definition, and investigated the relationship between response and clinical outcomes. Results: The echocardiographic response rate was 74.2%. The functional response rate was 86.9%. Non-responder status, based on both definitions, was associated with higher all-cause mortality. Cardiac death was only associated with functional non-responder status (hazard ratio (HR) 2.65, 95% confidence interval (CI) 1.19–5.46, p = 0.0186) and heart failure hospitalization (HR 2.78, 95% CI, 1.29–5.26, p = 0.0111). Conclusion: After CRT implantation, the functional response definition of CRT response is associated with a higher response rate and better clinical outcomes than that of the echocardiographic response definition, and therefore it is reasonable to use the functional definition to assess CRT response.

18 February 2021 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
NONaoto Otsuka
Naoto Otsuka
YOYasuo Okumura
Yasuo Okumura
MAMasaru Arai
Masaru Arai
SKSayaka Kurokawa
Sayaka Kurokawa
KNKoichi Nagashima
Koichi Nagashima
YLYxin Li
Yxin Li

21 November 2012 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
YOYasuo Okumura
Yasuo Okumura
IWIchiro Watanabe
Ichiro Watanabe
MKMasayoshi Kofune
Masayoshi Kofune
KNKoichi Nagashima
Koichi Nagashima
KSKazumasa Sonoda
Kazumasa Sonoda
AHAtsushi Hirayama
Atsushi Hirayama

17 December 2011 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
YOYasuo Okumura
Yasuo Okumura
IWIchiro Watanabe
Ichiro Watanabe
MKMasayoshi Kofune
Masayoshi Kofune
KNKoichi Nagashima
Koichi Nagashima
KSKazumasa Sonoda
Kazumasa Sonoda
AHAtsushi Hirayama
Atsushi Hirayama

1 July 2005 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
HSHidezou Sugimura
Hidezou Sugimura
IWIchiro Watanabe
Ichiro Watanabe
YOYasuo Okumura
Yasuo Okumura
KOKimie Ohkubo
Kimie Ohkubo
SASonoko Ashino
Sonoko Ashino
SSSatoshi Saito
Satoshi Saito